Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Worse QoL seen in hidradenitis suppurativa than psoriasis patients

24 Nov 2017

It appears that patients with psoriasis have lesser health-related quality of life (HRQoL) burden than those with hidradenitis suppurativa (HS), a recent study has found.

“This study clearly documents the needs of patients with HS and the potential impact of medical, scientific and societal consensus for the development of more effective HS treatments,” the investigators said.

To determine which diseases were associated with more severe HRQoL impairment, the investigators determined and compared weighted averages of each of the following baseline HRQoL measures between HS and psoriasis populations from five clinical trials: Visual Analogue Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index, EuroQOL 5D VAS and Short Form-36 Health Survey.

Patients with HS had higher scores for VAS-pain (54.3 vs 36.1 percent; p<0.001), Dermatology Life Quality Index (15.3 vs 11.3; p<0.0001), EuroQOL 5D VAS (58.8 vs 50.8; p<0.0002) and Total Work Productivity Impairment (35.4 vs 18.2) than did those with psoriasis. On the other hand, patients with psoriasis had higher Short Form-36 Health Survey scores compared with those with HS (physical, 39.6 vs 49.0; mental, 41.5 vs 47.5; p<0.0001 for both).

These findings should be taken in light of some limitations, such as the use of published summary data instead of patient-level data for the analysis, as well as the comparison of weighted pooled averages.

“Psoriasis and HS exhibit distinct clinical features, but no studies have directly compared the HRQoL in patients with moderate-to-severe manifestations of these conditions,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.